(MENAFN- GlobeNewsWire - Nasdaq)
LONDON and BOSTON, Nov. 24, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in the multi-billion-dollar market, announces that the board of directors of the Company (the ' Board ' or ' Directors '), acting on a recommendation of the Remuneration Committee has awarded Mr Raj Patil, the Company's Chief Scientific Officer, a total of 5,000,000 options at an exercise price of 6.25 pence per share, in recognition of his work in achieving the recent IND filing for OK-101. The options vest immediately and have a life of five years.
This information set out below is provided in accordance with Article 19(3) of UK MAR.
| 1 || Details of PDMR / person closely associated |
| a) || Name || Raj Patil |
| 2 || Reason for the notification |
| a) || Position / status || Chief Scientific Officer |
| b) || Initial notification /amendment || Initial notification |
| 3 || Details of the issuer |
| a) || Name || OKYO Pharma Limited |
| b) || LEI || 213800VVN5CB56Y15A05 |
| 4 || Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
| a) || Description of the financial instrument || Ordinary Shares of no par value |
| b) || Identification code of the Financial Instrument || ISIN for OKYO Pharma Limited: GG00BD3FV870 |
| c) || Nature of the transaction || Grant of options |
| d) || Price(s) and volume(s) || Price || Volume |
| 6.25p || 5,000,000 |
| f) || Date of the transaction || 22 November 2022 |
| || || |
| g) || Place of the transaction || XLON |
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF DOMESTIC UK LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) ('UK MAR').
| OKYO Pharma Limited || Gary S. Jacob, Chief Executive Officer |
| +44 (0)20 7495 2379 |
| || || |
| Optiva Securities Limited |
| Robert Emmet || +44 (0)20 3981 4173 |
| || || |
| LifeSci Advisors |
| Irina Koffler || Irina Koffler |
Notes for Editors:
OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) is a life sciences company admitted to listing on NASDAQ and on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the main market for listed securities of London Stock Exchange plc. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain.
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.